59-Year-Old Sheds 25 Pounds with New Foundayo GLP-1 Pill

The U.S. Food and Drug Administration approved Eli Lilly’s Foundayo on Wednesday. The drug is the first once-daily GLP-1 pill that patients can take at any time.

How Foundayo differs from existing options

Until now, GLP-1 treatments came as refrigerated weekly injections. Examples include Ozempic, Wegovy, and Zepbound. Oral alternatives required a morning dose on an empty stomach, like Rybelsus and the Wegovy pill from Novo Nordisk.

Foundayo, generically named orforgipron, removes that timing restriction. It can be taken alongside other medications at any hour.

Clinical trial and a patient’s results

Eli Lilly ran an 18-month clinical trial across 2024 and 2025. One participant was a 59-year-old man from New Jersey named Adam Salberg.

He joined after seeing a trial invitation by email. He said prior diet and exercise had not delivered lasting results when he spoke to Filmogaz.com.

Early effects and weight loss

Salberg reported the first change on the fifth day. He felt satisfied with a smaller dinner portion.

After two months he had lost seven pounds. He then lost five more the next month. By the trial’s end he was 25 pounds lighter and had tightened his belt by two notches.

Post-trial maintenance

Salberg kept most of the weight off after the study ended. His appetite returned about six weeks after stopping the medication. Some weight returned, but not to his starting point.

He credits portion control and continued exercise for maintenance. He plans to discuss restarting the drug with his doctor if insurance covers it.

How the drug works

GLP-1 drugs mimic the body’s glucagon-like peptide 1. They prolong the hormone’s effect, slow digestion, and reduce hunger.

The medications also help control blood sugar. Foundayo operates on the same physiological principles as other GLP-1 therapies.

Side effects reported in trials

Participants commonly experienced gastrointestinal effects. Nausea occurred in roughly 29 to 34 percent of patients, depending on dose.

Constipation appeared in 22 to 25 percent. Diarrhea affected 21 to 23 percent, and vomiting ranged from 13 to 24 percent. Slowed digestion was a prominent symptom for some users.

Lifestyle changes during treatment

During the trial Salberg adopted regular exercise three times weekly. He combined cardio and strength training to help protect muscle mass.

He also shifted to a Mediterranean-style diet. He increased lean proteins and vegetables and cut red meat and saturated fats.

Market impact and pricing

Analysts say Foundayo could expand the global market for GLP-1 therapies. Millions may prefer a convenient daily pill they can take anytime.

Eli Lilly lists cash prices between $149 and $349 per month, depending on dose. If covered by insurance, monthly out-of-pocket costs could be as low as $25.

The trial underscores how a new GLP-1 pill can change appetite and weight. Filmogaz.com will continue to follow developments and access updates.